Halozyme Therapeutics (HALO) Other Non-Current Assets (2012 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Other Non-Current Assets data on file, last reported at $15.3 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 3.8% year-over-year to $15.3 million in Q1 2026; TTM through Mar 2026 was $15.3 million, a 3.8% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, changed N/A from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $15.3 million, up from $2.6 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for HALO reached as high as $56.4 million in Q2 2025 and fell as low as $500000.0 in Q1 2022.
• Historically, Other Non-Current Assets has averaged $18.0 million across 5 years, with a median of $15.9 million in 2024.
• Across the five-year window, Other Non-Current Assets sank 96.77% in 2022 and surged 1384.8% in 2023, its largest moves.
• Year by year, Other Non-Current Assets stood at $500000.0 in 2022, then jumped by 3523.0% to $18.1 million in 2023, then dropped by 8.56% to $16.6 million in 2024, then sank by 84.3% to $2.6 million in 2025, then soared by 487.81% to $15.3 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $15.3 million in Q1 2026, $2.6 million in Q4 2025, and $55.7 million in Q3 2025.